id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308085-x00c3eex	Kirsch, David G.	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable	2020-05-12		.txt	text/plain	2279	118	51	As far as we are aware, there are only a small number of case series of patients with viral pneumonia treated with low dose thoracic radiation therapy that have been reported. Oppenheimer concluded that "roentgen therapy of virus pneumonia is useful mainly during the early stages of disease." These findings suggest that even if low dose thoracic radiotherapy has any efficacy in patients with COVID-19, it may not be useful in later stages of the disease once hypoxia or ARDS develop. The authors concluded that "roentgen therapy instituted 24 hours after viral inoculation of mice with swine influenza has no effect on the mortality of this disease." Taken together, these preclinical data are insufficient to support a clinical trial of low dose radiation therapy in patients with COVID-19. As there are currently no approved treatments for COVID-19, some have suggested that 0.5 to 1 Gy of whole thorax radiation therapy would present a very low risk to COVID-19 patients in a clinical trial [9] .	./cache/cord-308085-x00c3eex.txt	./txt/cord-308085-x00c3eex.txt